Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
remab
- Development stage
- Unknown
- Lead developer
- Eskayef Pharmaceuticals
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Remab is a rituximab biosimilar developed and marketed by Eskayef Pharmaceuticals (SK+F) in Bangladesh. It is a genetically engineered chimeric murine/human monoclonal IgG1 kappa antibody directed against the CD20 antigen, which is primarily found on the surface of B-lymphocytes. The binding of Remab to CD20 initiates B-cell lysis through several mechanisms, including complement-dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC). Remab is approved for the treatment of various B-cell mediated conditions, such as Non-Hodgkin's Lymphoma (NHL), Chronic Lymphocytic Leukemia (CLL), Rheumatoid Arthritis (RA), Granulomatosis with Polyangiitis (GPA), Microscopic Polyangiitis (MPA), and Pemphigus Vulgaris (PV). It is administered as an intravenous injection and is available in 100 mg/10 mL and 500 mg/50 mL formulations.
- Brand names
- Remab
- Other names
- Rituximab InjectionRituximab
02
Targets
Beyond the preview
Go deeper on remab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on remab.